Literature DB >> 25787982

Identification and characterization of a novel scFv recognizing human and mouse CD133.

Suresh Kumar Swaminathan1, Lin Niu, Nate Waldron, Steve Kalscheuer, David M Zellmer, Michael R Olin, John R Ohlfest, Daniel A Vallera, Jayanth Panyam.   

Abstract

CD133, also known as Prominin-1, is expressed on stem cells present in many tissues and tumors. In this work, we have identified and characterized a single-chain variable fragment (scFv) for the efficient and specific recognition of CD133. Phage display was used to develop the scFv from a previously reported anti-CD133 hybridoma clone 7, which was capable of recognizing both glycosylated and non-glycosylated forms of human CD133. The scFv immunostained CD133(+) Caco-2 cells, but not CD133(-/low) U87 cells. Significantly, it immunostained CD133(-) cells transiently transfected with the mouse CD133 gene as well as CD133(+) mouse cells. Co-immunostaining studies in mouse bone marrow cells, using anti-CD133 scFv-FITC and anti-mouse CD133-PE (clone 13A4) commercial antibody, indicated that the epitopes recognized by these reagents partially overlap. Taken together, these results suggest that the scFv can recognize mouse CD133 protein in addition to recognizing human CD133. This new scFv is expected to be valuable both as a molecular diagnostic reagent for identifying CD133(+) cells and as a ligand for targeting therapeutics to CD133(+) tumor-initiating cells.

Entities:  

Year:  2013        PMID: 25787982      PMCID: PMC5527709          DOI: 10.1007/s13346-012-0099-6

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  24 in total

1.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

2.  A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.

Authors:  S Miraglia; W Godfrey; A H Yin; K Atkins; R Warnke; J T Holden; R A Bray; E K Waller; D W Buck
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

3.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

Authors:  M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS.

Authors:  Takuya Sugiyama; Ryan T Rodriguez; Graeme W McLean; Seung K Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

5.  Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane.

Authors:  K Röper; D Corbeil; W B Huttner
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

6.  Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.

Authors:  Mareike Florek; Michael Haase; Anne-Marie Marzesco; Daniel Freund; Gerhard Ehninger; Wieland B Huttner; Denis Corbeil
Journal:  Cell Tissue Res       Date:  2004-11-19       Impact factor: 5.249

Review 7.  Therapeutic implications of colon cancer stem cells.

Authors:  Eros Fabrizi; Simona di Martino; Federica Pelacchi; Lucia Ricci-Vitiani
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

Review 8.  AC133/CD133/Prominin-1.

Authors:  Sergey V Shmelkov; Ryan St Clair; David Lyden; Shahin Rafii
Journal:  Int J Biochem Cell Biol       Date:  2005-04       Impact factor: 5.085

Review 9.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.

Authors:  Scott Bidlingmaier; Xiaodong Zhu; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2008-06-06       Impact factor: 4.599

10.  Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Authors:  Nate N Waldron; Dan S Kaufman; Seunguk Oh; Zintis Inde; Melinda K Hexum; John R Ohlfest; Daniel A Vallera
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.009

View more
  8 in total

1.  A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Authors:  Nate N Waldron; Sanford H Barsky; Phillip R Dougherty; Daniel A Vallera
Journal:  Target Oncol       Date:  2013-07-31       Impact factor: 4.493

2.  Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Authors:  J U Schmohl; M K Gleason; P R Dougherty; J S Miller; D A Vallera
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

3.  Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Authors:  Amy P N Skubitz; Elizabeth P Taras; Kristin L M Boylan; Nate N Waldron; Seunguk Oh; Angela Panoskaltsis-Mortari; Daniel A Vallera
Journal:  Gynecol Oncol       Date:  2013-05-27       Impact factor: 5.482

Review 4.  CD133, Selectively Targeting the Root of Cancer.

Authors:  Jörg U Schmohl; Daniel A Vallera
Journal:  Toxins (Basel)       Date:  2016-05-28       Impact factor: 4.546

5.  Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Jörg U Schmohl; Martin Felices; Felix Oh; Alexander J Lenvik; Aaron M Lebeau; Jayanth Panyam; Jeffrey S Miller; Daniel A Vallera
Journal:  Cancer Res Treat       Date:  2017-02-20       Impact factor: 4.679

Review 6.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

Review 7.  Development of therapeutic antibodies for the treatment of diseases.

Authors:  Ruei-Min Lu; Yu-Chyi Hwang; I-Ju Liu; Chi-Chiu Lee; Han-Zen Tsai; Hsin-Jung Li; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2020-01-02       Impact factor: 8.410

8.  Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization.

Authors:  Cathrine Elisabeth Olsen; Lawrence H Cheung; Anette Weyergang; Kristian Berg; Daniel A Vallera; Michael G Rosenblum; Pål Kristian Selbo
Journal:  J Clin Med       Date:  2019-12-26       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.